Point Therapeutics to Host Second Quarter 2006 Results Conference Call/Audio Webcast
August 02 2006 - 8:23AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP), announced today that it
will release second quarter 2006 results on Tuesday, August 8,
2006, after the close of the U.S. financial markets. A conference
call will follow at 4:30 PM Eastern Time, to review the results and
provide an update on the Company's progress. Participants are
invited to attend the call by visiting www.pther.com or by dialing:
866-202-3048 (International: 617-213-8843) Passcode: 12632977 A
re-broadcast of the conference call will be available until August
15, 2006 and accessible by dialing: 888-286-8010 (International:
617-801-6888) Passcode: 51903272 About Point Therapeutics, Inc.:
Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in
cancer, type 2 diabetes and as vaccine adjuvants. Point is
currently studying its lead product candidate, talabostat, in two
Phase 3 trials in non-small cell lung cancer. Point is also
studying talabostat in several Phase 2 trials, including as a
single-agent in metastatic melanoma, in combination with cisplatin
in metastatic melanoma, in combination with rituximab in advanced
chronic lymphocytic leukemia, and in combination with gemcitabine
in metastatic pancreatic cancer. In addition, Point's portfolio
includes two other DPP inhibitors in preclinical
development--PT-630 for type 2 diabetes, and PT-510 as a vaccine
adjuvant.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Oct 2023 to Oct 2024